SG-based Mirxes to join Hang Seng Composite Index

It will be amongst the 17 biotech stocks included in the index.

Singapore-based molecular cancer early detection company Mirxes has been named a new constituent of the Hang Seng Composite Index (HSCI).

According to the company, this development came three months after its debut at the Hong Kong Stock Exchange.

“Mirxes will be amongst the 17 biotech stocks included in the HSCI after this review, out of 76 biotech companies listed on HKEX through the Chapter 18A route since 2018,” the company said.

Mirxes said its inclusion in the HSCI brings several key advantages, including increased visibility and liquidity, making it more attractive to a broader range of investors, particularly institutional investors and index funds that track the performance of the Hong Kong market.

This also opens up its stock to Mainland China investors, significantly expanding its investor base.

All changes will be implemented after market close on 5 September and take effect on 8 September.